Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
Hoffmann-La Roche
National Cancer Institute (NCI)
University of Michigan Rogel Cancer Center
UNC Lineberger Comprehensive Cancer Center
University of Michigan Rogel Cancer Center
Incyte Corporation
Gilead Sciences
National Cancer Institute (NCI)
Hoffmann-La Roche
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
University of Michigan Rogel Cancer Center
University of Chicago
University of Chicago
Thomas Jefferson University
Eastern Cooperative Oncology Group
University of Chicago
M.D. Anderson Cancer Center
Stanford University
Bristol-Myers Squibb
Eastern Cooperative Oncology Group
Tessa Therapeutics
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Michigan Rogel Cancer Center
University of California, Davis
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
Celgene
Eli Lilly and Company
University of Maryland, Baltimore
Memorial Sloan Kettering Cancer Center
University of Florida
Daiichi Sankyo
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Northwell Health
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
University of Maryland, Baltimore
University of Michigan Rogel Cancer Center
Emory University
Mateon Therapeutics
University of Alabama at Birmingham
M.D. Anderson Cancer Center